Impact of post-procedural glycemic variability on cardiovascular morbidity and mortality after transcatheter aortic valve implantation: a post hoc cohort analysis

Table 3 Comparison of blood glucose control parameters within the first 48 after TAVI between patients who underwent or not a post-procedural major adverse event

	MAE− (n = 124)	MAE+ (n = 36)	p value
Blood glucose control parameters
Number of blood glucose measurements per patient^a	16 [12–19]	18 [14–20]	0.03
Average blood glucose value (mmol l⁻¹)^a	7.1 [6.6–7.8]	7.2 [6.5–8.1]	0.54
Percentage of blood glucose values within 4.4–8.2 mmol l⁻¹	67 [51–79]	58 [41–75]	0.08
Hyperglycemia^b	77 (62)	26 (72)	0.26
Moderate hypoglycemia^c	20 (16)	9 (25)	0.23
Severe hypoglycemia^d	3 (2)	2 (6)	0.31
Insulin consumption
Total dose of insulin infused (IU/l)^a	12 [4–19]	13 [3–30]	0.40
Glycemic variability
Mean daily δ blood glucose (mmol l⁻¹)^a	4.0 [2.9–5.3]	5.4 [4.1–7.7]	0.001
Standard deviation of blood glucose value (mmol l⁻¹)^a	1.6 [1.1–2.0]	1.8 [1.5–2.4]	0.01
Coefficient of variability of blood glucose (%)^a	22 [17–27]	24 [22–34]	0.007

Data are number of patients (percentage)
MAE, major adverse event
^aData are median [interquartile range 25–75%]
^bHyperglycemia was defined as two consecutive blood glucose values ≥ 8.2 mmol l⁻¹
^cModerate hypoglycemia was defined as a blood glucose value < 3.8 mmol l⁻¹
^dSevere hypoglycemia was defined as a blood glucose value < 2.2 mmol l⁻¹

ISSN: 1475-2840